By Professor Elgene Lim

Conference Papers

Lien YTK; Jhaveri K; Turner N; Lim E; Cannon M; Anziano R; Langenhorst J; Yoshida K; Malhi V; Gates M; Eng-Wong J; Li C; Shah M; Pérez-Moreno P; Yu J; Bardia A, 2024, 'Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer', in Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, International Society of Pharmacometrics, presented at American Conference of Pharmacometrics, http://dx.doi.org/10.70534/mqct2577

Collier A; Mac Gregor MC; Hilz S; Bardia A; Sohn J; Martin M; Lim E; Martinalbo J; Perez-Moreno PD; Moore HM, 2023, 'Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2-aBC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Jhaveri KL; Jeselsohn R; Lim E; Hamilton EP; Yonemori K; Beck JT; Kaufman PA; Sammons S; Bhave MA; Saura C; Calvo E; Meniawy T; Larson T; Ma CX; Garcia-Corbacho J; Cao S; Estrem ST; Milata JL; Nguyen B; Beeram M, 2022, 'A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER plus ) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lim E; Brufsky A; Rugo HS; Vogel CL; O'Shaughnessy J; Getzenberg RH; Barnette KG; Rodriguez D; Bird G; Steiner MS; Linden HM, 2022, 'Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2-metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Wu SZ; Roden D; Eryani GA; Junankar S; Lim E; Thennavan A; Andersson A; Williams S; Gong J; Fropf R; Fuhrman K; Lundeberg J; Perou C; Swarbrick A, 2021, 'Abstract 129: An integrated multi-omic cellular atlas of human breast cancers', in Cancer Research, American Association for Cancer Research (AACR), pp. 129 - 129, http://dx.doi.org/10.1158/1538-7445.am2021-129

Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SR; Smyth LM; Hamilton EP, 2021, 'Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer', in Cancer Research, American Association for Cancer Research (AACR), pp. ot-09-03-ot-09-03, http://dx.doi.org/10.1158/1538-7445.sabcs20-ot-09-03

Lau B; Segara D; Ong A; Bingham J; Kiely B; Carson E-K; Chen J; Mak C; Warrier S; Hui M; Middleton K; Parker A; Mann B; Lindeman G; Tilley W; Lim E, 2021, 'Abstract OT-09-07: Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), pp. ot-09-07-ot-09-07, http://dx.doi.org/10.1158/1538-7445.sabcs20-ot-09-07

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O’Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2021, 'Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study', in Cancer Research, American Association for Cancer Research (AACR), pp. pd8-10-pd8-10, http://dx.doi.org/10.1158/1538-7445.sabcs20-pd8-10

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), pp. ps18-17-ps18-17, http://dx.doi.org/10.1158/1538-7445.sabcs20-ps18-17

Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Gable JC; Price GL; Hossain A; Gainford M; Ezquerra MB, 2020, 'The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 124 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400152&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lim E; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon EC; Portman N, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 110 - 110

Metzger-Filho O; Mandrekar S; Loibl S; Ciruelos E; Gianni L; Lim E; Miller K; Huang C; Koehler M; Francis P; Valagussa P; Goel S; Prat A; Goetz M; Loi S; Krop I; Carey L; Lanzillotti J; Winer E; Tripathy D; DeMichele A, 2018, 'Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer', in Cancer Research, American Association for Cancer Research (AACR), pp. ot3-05-07-ot3-05-07, http://dx.doi.org/10.1158/1538-7445.sabcs17-ot3-05-07

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2018, 'Abstract P4-04-12: Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), pp. p4-04-12-p4-04-12, http://dx.doi.org/10.1158/1538-7445.sabcs17-p4-04-12

Singhal H; Chi D; Lim E; He H; Vadhi R; Rao PK; Long HW; Richardson AL; Garber J; Brown M, 2017, 'Abstract LB-257: Estrogen signaling in mature luminal and luminal progenitor cells of BRCA2 carriers and non-carriers', in Cancer Research, American Association for Cancer Research (AACR), pp. lb-257-lb-257, http://dx.doi.org/10.1158/1538-7445.am2017-lb-257

Johnson S; Johnson N; Chi D; Primack B; Cruz C; Stover D; Greifenberg AK; Cao S; O'Connor K; Baselga J; Balmana J; Serra V; Geyer M; D'Andrea A; Lim E; Shapiro GI, 2014, 'Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 80 - 80, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70364-8

Lim E; He HH; Chi D; Garber JE; Richardson A; Brown M, 2012, 'Estrogen receptor (ER) signaling in normal, BRCA (B) 1 and B2 mutation associated, and ER-positive breast cancer (BC) mammary cells.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009800130&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lindeman GJ; Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE, 2011, 'PD08-02: Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics – A New Class of Drugs in Breast Cancer?', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/0008-5472.sabcs11-pd08-02

Lindeman GJ; Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DCS; Visvader JE, 2011, 'Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics - A New Class of Drugs in Breast Cancer?', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS11-PDOS-02

Visvader JE; Asselin-Labat M-L; Vaillant F; Lim E; Bouras T; Pal B; Wu D; Smyth G; Lindeman G, 2011, 'Getting abreast of the mammary epithelial hierarchy and breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.AM2011-SY12-03

Lim E; Winer EP, 2011, 'Adjuvant chemotherapy in luminal breast cancers', in Breast, pp. S128 - S131, http://dx.doi.org/10.1016/S0960-9776(11)70309-5

Lim E; Wu D; Pal B; Bouras T; Asselin-Labat M-L; Vaillant F; Yagita H; Lindeman GJ; Smyth GK; Visvader JE, 2010, 'Transcriptome Analyses of Mouse and Human Mammary Cell Subpopulations Reveals Multiple Conserved Genes and Pathways', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS10-P4-04-03

Lim E; Vaillant F; Wu D; Forrest N; Pal B; Gyorki D; Smyth GK; Visvader J; Lindeman G, 2009, 'Investigation of human mammary stem and progenitor subpopulations from BRCA1 mutation carriers and noncarriers', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606601221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters

Turner NC; Loi S; Moore HM; Chang C-W; Eng-Wong J; Bardia A; Boni V; Sohn J; Jhaveri KL; Lim E, 2022, 'Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC)', Vol. 82, pp. pd13-07-pd13-07, http://dx.doi.org/10.1158/1538-7445.sabcs21-pd13-07

Conference Abstracts

Tran M; Saw K; Mo J; Carson E-K; MacDonald K; Lloyd M; Rossiter G; Crawford M; Mazariego C; Dadich A; Brydon P; River J; Dear RF-G; Lim E; Lin FP-Y, 2026, 'Patient preference for large language model (LLM)–optimised oncology trial information: A randomised controlled crossover study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. 6 - 6, http://dx.doi.org/10.1200/jco.2026.44.19_suppl.6

Lobanov AV; Kim HJ; Kanwal S; Harvey K; Reeves J; Batten M; Kiedik B; Roden DL; Hui MN; Stewart KP; Hofmann O; O’Toole S; Lim E; Grimmond SM; Swarbrick A; Perou CM, 2026, 'Abstract 44: scSubtype2.0: Predictor of breast cancer molecular subtypes at single cell resolution.', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. 44 - 44, http://dx.doi.org/10.1158/1538-7445.am2026-44

Kim HJ; Kiedik B; Harvey K; Kanwal S; Douglas J; Reeves J; Lobanov A; Roden DL; Van Der Leij S; Hui MN; Al’Khafaji A; Lim E; Grimmond SM; Lundeberg J; Perou CM; Swarbrick A, 2026, 'Abstract 7282: A comprehensive multiomics atlas of treatment-naïve breast cancer uncovers co-occurring tumor-immune ecosystems driving immune hot and cold phenotypes', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. 7282 - 7282, http://dx.doi.org/10.1158/1538-7445.am2026-7282

Jhaveri K; Neven P; Casalnuovo ML; Kim S-B; Tokunaga E; Aftimos P; Saura C; O’Shaughnessy J; Harbeck N; Carey LA; Curigliano G; Llombart-Cussac A; Lim E; Luz García Tinoco MDL; Sohn J; Mattar A; Zhang Q; Huang C-S; Hung C-C; Martinez Rodriguez JL; Borrego MR; Nakamura R; Pradhan KR; Cramer von Laue C; Barrett E; Cao S; Wang XA; Smyth LM; Bidard F-C, 2025, 'Abstract GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy & Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial', in Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 31, pp. gs1-01-gs1-01, http://dx.doi.org/10.1158/1557-3265.sabcs24-gs1-01

Kiedik B; Roden DL; Harvey K; Al-Eryani G; Wu SZ; Hui MN; O’Toole S; Lim E; Perou CM; Swarbrick A, 2025, 'Abstract P4-09-19: Exploring cellular heterogeneity of localised breast cancers', in Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 31, pp. p4-09-19-p4-09-19, http://dx.doi.org/10.1158/1557-3265.sabcs24-p4-09-19

Jhaveri K; Nakajima TE; Giordano A; Juric D; Ma C; Unni N; Goetz MP; Kitano S; Loi S; Rugo H; Bidard F-C; Saura C; Lim E; Neven P; O’Shaughnessy J; Bhave M; Tan TJ; Bedard PL; Vanacker H; O’Regan R; Turner NC; Cortes J; Chia S; Campone M; Chau V; Hanley MP; Du L; Lombard A; Ramstetter M; Estrem S; Meric-Bernstam F, 2025, 'Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study', in Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 31, pp. ps7-03-ps7-03, http://dx.doi.org/10.1158/1557-3265.sabcs24-ps7-03

Howard FM; Fasching PA; Santa-Maria CA; Lim E; Sparano J; Lustberg M; Bachelot T; Blyuss O; Brezden-Masley C; Park YH; Akdere M; Ye F; Pantoja K; Castro PD; Kurz C; Razavi P, 2025, '372P A NATALEE data–based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx', in Annals of Oncology, Elsevier, Vol. 36, pp. s358, http://dx.doi.org/10.1016/j.annonc.2025.08.797

Fasching PA; Barrios CH; Lim E; Graff SL; Chia S; Frenel J-S; Im S-A; Huang C-S; Ring A; Nowecki Z; Liu Q; Akdere M; Zarate JP; Hu H; Pantoja K; O'Shaughnessy JA, 2025, 'P001: Prognostic variables for risk of recurrence in patients (pts) with HR+/HER2–early breast cancer (EBC) using data from the NATALEE trial: a machine learning (ML) model–based analysis', in The Breast, Elsevier, Vol. 80, pp. 103895, http://dx.doi.org/10.1016/j.breast.2025.103895

Kiedik B; Roden D; Harvey K; Al-Eryani G; Wu S; Hui M; O'Toole S; Lim E; Perou C; Swarbrick A, 2024, 'Abstract PO5-01-09: Exploring cellular heterogeneity of localised breast cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. po5-01-09-po5-01-09, http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-01-09

Freelander A; Laven-Law G; Eshraghi L; Geetha N; Somerville P; Pickering M; Alexandrou S; Caldon CE; Tilley WD; Hickey TE; Lim E, 2022, 'Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER plus AR plus breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 83, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2022 - 10 December 2022, http://dx.doi.org/10.1158/1538-7445.SABCS22-P4-08-16

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2-metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown LJ; Dear RF-G; Chan L; Pathmanandavel S; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '⁶⁴Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3092

Jhaveri KL; Jeselsohn R; Lim E; Hamilton EP; Yonemori K; Beck JT; Kaufman PA; Sammons S; Bhave MA; Saura C; Calvo E; Meniawy T; Larson T; X. C; García-Corbacho J; Cao S; Estrem ST; Milata JL; Nguyen B; Beeram M, 2022, 'A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 1021 - 1021, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1021

Lim E; Brufsky A; Rugo HS; Vogel CL; O'Shaughnessy J; Getzenberg RH; Barnette KG; Rodriguez D; Bird G; Steiner MS; Linden HM, 2022, 'Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. tps1121 - tps1121, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps1121

Freelander A; Laven-Law G; Eshraghi L; Chia KM; Pickering M; Yong A; Wilkinson A; Alexandrou S; Caldon CE; Hickey TE; Tilley WD; Lim E, 2022, 'Abstract PD2-02: Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. pd2-02-pd2-02, http://dx.doi.org/10.1158/1538-7445.sabcs21-pd2-02

Brown LJ; Meredith T; Yu J; Patel A; Neal B; Arnott C; Lim E, 2021, 'Heart failure therapies for the prevention of HER2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wong V; De Boer R; Baron-Hay S; Blum R; Forster B; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott LW; Nottage M; Tafreshi A; Tsoi D; Uccelini A; Gibbs P; Lok SW, 2021, 'Patient-reported outcomes of medicine access programmes: A sub-study of KARMA (Kisqali Access Registry for Metastatic Breast Cancer in Australia)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 175 - 176, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore HM; Boni V; Bellet M; De Las Heras BB; Cortés MG; Oakman C; Schmid P; Trinh XB; Wheatley D; Jhaveri KL; Kabos P; Lim E; Velu T; Metcalfe C; Gates MR; Chang C-W; Bond J; Goldstein LD; Lauchle JO; Bardia A, 2021, 'Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, pp. 577 - 577, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.577

Sheehan-Dare G; Lim E; Koo CM; Chan L; Lau B; Dear R; Ho B; Sharma S; Hickey A; Malaroda A; Smith I; Nguyen A; Parker M; Emmett L, 2021, 'Preliminary assessment of the diagnostic value of Cu-64-SAR-Bombesin PET-CT imaging for staging of ER+/PR+HER2-metastatic breast cancer disease: comparison with conventional imaging', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713713600278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wu SZ; Roden D; Al Eryani G; Junankar S; Lim E; Thennavan A; Andersson A; Williams S; Gong J; Fropf R; Fuhrman K; Lundeberg J; Perou C; Swarbrick A, 2021, 'An integrated multi-omic cellular atlas of human breast cancers.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 81, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy J; Johnston SRD; Getzenberg RH; Barnette KG; Steiner M; Brufsky AM; Overmoyer B, 2021, '100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study', in Annals of Oncology, Elsevier, Vol. 32, pp. s66, http://dx.doi.org/10.1016/j.annonc.2021.03.114

Yap Y-S; Kim S-B; Chiu JWY; Lim E; Broom R; Liu Z; Sagara Y; Chao T-Y; Sherwood S; McNaughton RE; Wei RJ; Toi M, 2021, '48P Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE', in Annals of Oncology, Elsevier, Vol. 32, pp. s41 - s42, http://dx.doi.org/10.1016/j.annonc.2021.03.062

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2020, 'Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020

Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SRL; Smyth LM; Hamilton EP, 2020, 'EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER plus breast cancer and endometroid endometrial cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2020, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020

Lim E, 2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology, Chicago, presented at American Society of Clinical Oncology, Chicago, 29 May 2020 - 31 May 2020

Lok SW; Baron-Hay S; Lim E; Blum R; Boyle F; Clarke K; Cuff K; Green M; Malik L; Mok K; Murray N; Nott L; Nottage M; Tafreshi A; Tsoi D; Yeo B; Gibbs P; De Boer R, 2020, 'Abstract OT2-02-01: A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. ot2-02-01-ot2-02-01, http://dx.doi.org/10.1158/1538-7445.sabcs19-ot2-02-01

Back to profile page